menu
    • menu

    Find Remimazolam Besylate manufacturers, exporters & distributors on PharmaCompass

    Client Email Product
    Seqens Remimazolam RMU

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Moehs Remimazolam

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    7

    API Suppliers

    API Suppliers

    3

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    1

    KDMF

    KDMF

    2

    NDC API

    NDC API

    0

    VMF

    NDC API

    5

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 43,980

    MARKET PLACE

    4

    API

    0

    FDF

    2INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    1

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    6DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    11

    US Patents

    1

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    8

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    NA

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 308242-62-8, Cns 7056, Cns-7056, Ono-2745, 7v4a8u16mb, 308242-62-8 (freee base)
    Molecular Formula
    C21H19BrN4O2
    Molecular Weight
    439.3  g/mol
    InChI Key
    CYHWMBVXXDIZNZ-KRWDZBQOSA-N
    FDA UNII
    7V4A8U16MB
    Remimazolam Besylate
    Remimazolam is a short-acting benzodiazepine derivative that is structurally related to midazolam, with sedative-hypnotic activity. Upon administration, remimazolam targets and binds to a specific site on the gamma-aminobutyric acid (GABA)-A-chloride ionophore receptor complex located on the neuronal membrane. Binding causes an allosteric modification of the receptor thereby enhancing the affinity of GABA to the receptor leading to an increase in the frequency of chloride-channel opening events, which leads to an increase in chloride ion conductance, neuronal hyperpolarization, inhibition of the action potential, and a decrease in neuronal excitability.
    1 2D Structure

    Remimazolam Besylate

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    methyl 3-[(4S)-8-bromo-1-methyl-6-pyridin-2-yl-4H-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate
    2.1.2 InChI
    InChI=1S/C21H19BrN4O2/c1-13-12-24-21-17(7-9-19(27)28-2)25-20(16-5-3-4-10-23-16)15-11-14(22)6-8-18(15)26(13)21/h3-6,8,10-12,17H,7,9H2,1-2H3/t17-/m0/s1
    2.1.3 InChI Key
    CYHWMBVXXDIZNZ-KRWDZBQOSA-N
    2.1.4 Canonical SMILES
    CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=NC2CCC(=O)OC)C4=CC=CC=N4
    2.1.5 Isomeric SMILES
    CC1=CN=C2N1C3=C(C=C(C=C3)Br)C(=N[C@H]2CCC(=O)OC)C4=CC=CC=N4
    2.2 Other Identifiers
    2.2.1 UNII
    7V4A8U16MB
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Cns 7056

    2. Methyl 3-(8-bromo-1-methyl-6-(2-pyridinyl)-4h-imidazo(1,2-a)(1,4)benzodiazepin-4-yl)propanoate

    3. Ono 2745

    4. Ono-2745

    5. Ono2745

    2.3.2 Depositor-Supplied Synonyms

    1. 308242-62-8

    2. Cns 7056

    3. Cns-7056

    4. Ono-2745

    5. 7v4a8u16mb

    6. 308242-62-8 (freee Base)

    7. 4h-imidazo(1,2-a)(1,4)benzodiazepine-4-propanoic Acid, 8-bromo-1-methyl-6-(2-pyridinyl)-, Methyl Ester, (4s)-

    8. Methyl (s)-3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4h-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate

    9. Remimazolam [inn]

    10. Unii-7v4a8u16mb

    11. Remimazolam [mi]

    12. Remimazolam (usan/inn)

    13. Remimazolam [usan:inn]

    14. Remimazolam [usan]

    15. Remimazolam [who-dd]

    16. Schembl846435

    17. Chembl4297526

    18. Dtxsid20953024

    19. Ono2745

    20. Amy15524

    21. Ex-a5536

    22. Ono 2745

    23. Who 9232

    24. Zinc3927450

    25. Akos025213215

    26. Db12404

    27. Hy-14867

    28. 4523b

    29. Cs-0003605

    30. D11788

    31. 4h-imidazol(1,2-a)(1,4)benzodiazepine-4-propionic Acid, (s)-

    32. (s)-methyl 3-(8-bromo-1-methyl-6-(pyridin-2-yl)-4h-benzo[f]imidazo[1,2-a][1,4]diazepin-4-yl)propanoate

    33. Methyl 3-((4s)-8-bromo-1-methyl-6-(pyridin-2-yl)-4h-imidazo(1,2-a)(1,4)benzodiazepin-4-yl)propanoate

    34. Methyl 3-[(4s)-8-bromo-1-methyl-6-(2-pyridyl)-4h-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate

    35. Methyl 3-[(4s)-8-bromo-1-methyl-6-pyridin-2-yl-4h-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate

    36. Methyl 3-[8-bromo-1-methyl-6-(pyridin-2-yl)-4h-imidazo[1,2-a][1,4]benzodiazepin-4-yl]propanoate

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 439.3 g/mol
    Molecular Formula C21H19BrN4O2
    XLogP33.4
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count5
    Exact Mass438.06914 g/mol
    Monoisotopic Mass438.06914 g/mol
    Topological Polar Surface Area69.4 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity601
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.

    FDA Label

    Remimazolam is indicated in adults for procedural sedation.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Remimazolam modulates the effects of GABA(A) receptors in order to enhance the effects of GABA. It is considered an "ultra short-acting" benzodiazepine that achieves peak sedation within 3 to 3.5 minutes following intravenous administration, a property that makes it desirable for use during short procedures. Hepatic impairment can result in elevated serum levels of remimazolam - patients with severe hepatic impairment should be carefully titrated to effect. As of its approval date, remimazolam has not received a scheduling action by the DEA under the Controlled Substances Act. As benzodiazepines as a class have been implicated in the development of drug dependence and have a known potential for abuse, remimazolam should be used with caution in patients with a history of drug dependence or abuse.

    5.2 ATC Code

    N05CD

    N - Nervous system

    N05 - Psycholeptics

    N05C - Hypnotics and sedatives

    N05CD - Benzodiazepine derivatives

    N05CD14 - Remimazolam

    5.3 Absorption, Distribution and Excretion

    Absorption

    The Cmax and AUC0-inf following intravenous administration of 0.01 to 0.5 mg/kg were 189 to 6,960 ng/mL and 12.1 to 452 ngh/mL, respectively, and appear to be relatively dose proportional. The Tmax of the inactive CNS7054 metabolite is approximately 20-30 minutes and its AUC0-inf ranges from 231 to 7,090 ngh/mL.

    Route of Elimination

    In patients undergoing colonoscopy, approximately 0.003% of the administered dose is excreted in the urine as unchanged parent drug and 50-60% is excreted in the urine as CNS7054. In healthy subjects, >80% of the administered dose is excreted in the urine as CNS7054.

    Volume of Distribution

    The volume of distribution is approximately 0.76 - 0.98 L/kg.

    Clearance

    The clearance of remimazolam is approximately 24 - 75 L/h and is independent of body weight.

    5.4 Metabolism/Metabolites

    Remimazolam does not appear to undergo biotransformation via hepatic cytochrome P450 enzymes, nor does it induce or inhibit these enzymes. Its primary route of metabolism is hydrolysis via hepatic carboxylesterase-1 (CES1) to yield the inactive CNS7054 metabolite, which then undergoes glucuronidation and hydroxylation prior to elimination. CNS7054 possesses a 300-fold lesser affinity for GABA(A) receptors as compared to the parent drug.

    5.5 Biological Half-Life

    Following intravenous administration, the distribution half-life is of remimazolam is 0.5 - 2 minutes and the terminal elimination half-life is 37 - 53 minutes. Half-life is increased in patients with hepatic impairment necessitating careful dose titration in this population. The half-life of remimazolam's major inactive metabolite, CNS7054, is 2.4 - 3.8 hours.

    5.6 Mechanism of Action

    Like other benzodiazepines, remimazolam exerts its therapeutic effects by potentiating the effect of gamma-aminobutyric acid (GABA) on GABA(A) receptors, the main inhibitory neurotransmitter receptors in the mammalian brain. GABA(A) receptors are a component of GABA-gated ionotropic chloride channels that produce inhibitory postsynaptic potentials - following activation by GABA, the channel undergoes a conformational change that allows the passage of chloride ions through the channel. The inhibitory potentials produced by GABA neurotransmission play an integral role in the suppression and control of epileptiform nerve firing such as that seen in epilepsy, which makes the GABA system a desirable target in the treatment of epilepsy. Benzodiazepines are positive allosteric modulators of GABA(A) function. They bind to the interface between alpha () and gamma () subunits on the receptor, commonly referred to as the benzodiazepine binding site, and modulate the receptor such that its inhibitory response to GABA binding is dramatically increased.

    API SUPPLIERS

    read-more
    read-more
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-more

    01

    Moehs Iberica Sl

    Spain
    arrow
    CPhI Worldwide, Milan
    Booth #4A33
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 36332

    Submission : 2021-10-07

    Status : Active

    Type : II

    Moehs Iberica

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Paion Uk Ltd

    United Kingdom

    USDMF

    arrow
    ASC 2024
    Not Confirmed

    02

    Paion Uk Ltd

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 32748

    Submission : 2019-03-15

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    ASC 2024
    Not Confirmed

    03

    Teva Pharmaceutical Industries Ltd

    Israel
    arrow
    ASC 2024
    Not Confirmed

    GDUFA

    DMF Review : Complete

    Rev. Date : 2024-08-29

    Pay. Date : 2024-05-01

    DMF Number : 39813

    Submission : 2024-05-30

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KDMF

    read-more
    read-more

    01

    Cambrex Corporation

    U.S.A
    ASC 2024
    Not Confirmed
    arrow

    Cambrex Corporation

    U.S.A
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Remimazolam besylate

    Registrant Name : Samoh Pharmaceutical Co., Ltd.

    Registration Date : 2021-01-07

    Registration Number : Su0106-1-ND

    Manufacturer Name : Cambrex, Karlskoga AB

    Manufacturer Address : Bjorkborn Industriomrade Karlskoga, 691 85 Sweden

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Listed Suppliers

    read-more
    read-more

    01

    Seqens

    France
    arrow
    CPhI Worldwide, Milan
    Booth #2B50
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Remimazolam

    About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...

    Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling up and manufacturing drug substances from the pre-clinical phase to the commercial phase. It offers a large portfolio of APIs and proprietary products. Seqens also develops custom solutions and ingredients for the most demanding industries, such as healthcare, electronics and cosmetics. Its unique range of technologies enables it to manufacture complex molecules for small- and large-scale demands. It operates 24 industrial plants and 10 R&D centres across the globe.
    Seqens Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Moehs Iberica

    Spain
    arrow
    CPhI Worldwide, Milan
    Booth #4A33
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMoehs Group, a reference company in the production of pharmaceutical active ingredients.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Remimazolam

    About the Company : Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 ...

    Since its founding in 1962, MOEHS has produced Active Pharmaceutical Ingredients (APIs) for the international pharmaceutical industry. Thanks to a business history of more than 50 years, MOEHS has considerable technical experience in the production of these substances. At Moehs Group we have a large tradition and experience in the area of manufacturing of active pharmaceutical and veterinary ingredients, agrochemicals, nutraceutical, cosmetic, as well as fine chemistry in general, with high levels of quality and safety standards-GMP´s, ICH, approved by the FDA and TGA.
    Moehs Iberica

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Cohance Lifesciences

    India
    arrow
    CPhI Worldwide, Milan
    Booth #4B1
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Remimazolam Besylate

    About the Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our...

    Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our expertise in complex chemistries, we provide end-to-end CDMO services to global innovators and have delivered numerous projects from concept to commercialization over the years.As a global API player, we serve customers across nearly 60 countries with 80+ molecules backed by robust R&D, regulatory capabilities and manufacturing infrastructure. We are among the top backward integrated exporters of pellets and have strong development and manufacturing capabilities.
    Cohance

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    ASolution Pharmaceuticals

    India
    arrow
    CPhI Worldwide, Milan
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothASolution Pharmaceuticals: Your Partner for cGMP Development & Manufacturing Services – Supplying APIs, FDFs, and Specialty Molecules.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Remimazolam Besylate

    About the Company : Since 2010, our dedication to our clientele has been unwavering in addressing pharmaceutical hurdles, regardless of scale. We prioritize integrity, responsiveness, and punctuality,...

    Since 2010, our dedication to our clientele has been unwavering in addressing pharmaceutical hurdles, regardless of scale. We prioritize integrity, responsiveness, and punctuality, embedding our values into every endeavor. Our aim is to cultivate mutually beneficial relationships with customers, suppliers, and ourselves, fostering sustainable growth. Empowered by visionary leadership and a quality-driven team, ASolution is steadfast in providing innovative solutions to challenges such as Process Development, Optimization, Drug Product and Substance Manufacturing, and more.
    ASolution Pharmaceuticals

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Harman Finochem

    India
    ASC 2024
    Not Confirmed
    arrow

    Harman Finochem

    India
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Remimazolam

    About the Company : Harman Finochem Limited is a leading India-based Pharmaceutical Company which specializes in the manufacture and export of more than 45 Active Pharmaceutical Ingredients (APls) of ...

    Harman Finochem Limited is a leading India-based Pharmaceutical Company which specializes in the manufacture and export of more than 45 Active Pharmaceutical Ingredients (APls) of which 10 are Essential Drugs as per the WHO Model List. We deliver top quality products to more than 35 countries across the globe. Harman Finochem ensures that its customers worldwide are delighted by receiving APl’s which are safe, efficient and of highest quality. We adhere to principles of cGmp and our team at all levels is committed to achieving this corporate excellence goal.
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711477800,"product":"REMIMAZOLAM BESYLATE","address":"1706,17TH FL KESAR SOLITAIRE PLOT","city":"NAVI MUMBAI, MAHARASHTRA","supplier":"ENALTEC LABS PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"N\/A","customer":"N\/A","customerCountry":"BRAZIL","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"60000","totalValueFC":"43979.8","currency":"USD","unitRateINR":3651900,"date":"27-Mar-2024","totalValueINR":"3651900","totalValueInUsd":"43979.8","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"8681381","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"1706,17TH FL KESAR SOLITAIRE PLOT, NAVI MUMBAI, MAHARASHTRA","customerAddress":""}]
    27-Mar-2024
    27-Mar-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acacia Pharma Launches BYFAVO in the U.S for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 30 Minutes or Less

    Details:

    BYFAVO is the second Acacia Pharma product approved and launched in the US in the last year and extends its portfolio of new products targeting unmet needs in anesthesia.


    Lead Product(s): Remimazolam Besylate

    Therapeutic Area: Neurology Brand Name: Byfavo

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 28, 2021

    blank

    01

    Acacia Pharma

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Acacia Pharma

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Remimazolam Besylate

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acacia Pharma Launches BYFAVO in the U.S for Procedural Sedation in Adults Undergoing Medical Proc...

    Details : BYFAVO is the second Acacia Pharma product approved and launched in the US in the last year and extends its portfolio of new products targeting unmet needs in anesthesia.

    Brand Name : Byfavo

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    January 28, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™

    Details:

    Under the Investment Agreement, Cosmo would have become eligible to receive a €5 million payment from the Company payable in new ordinary shares in the Company conditional upon the first commercial sale of the BYFAVO™ product in the United States.


    Lead Product(s): Remimazolam Besylate

    Therapeutic Area: Neurology Brand Name: Byfavo

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Acacia Pharma

    Deal Size: $45.0 million Upfront Cash: Undisclosed

    Deal Type: Agreement December 15, 2020

    blank

    02

    Cosmo Pharmaceuticals

    Ireland
    arrow
    ASC 2024
    Not Confirmed

    Cosmo Pharmaceuticals

    Ireland
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Remimazolam Besylate

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Acacia Pharma

    Deal Size : $45.0 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceutica...

    Details : Under the Investment Agreement, Cosmo would have become eligible to receive a €5 million payment from the Company payable in new ordinary shares in the Company conditional upon the first commercial sale of the BYFAVO™ product in the United States.

    Brand Name : Byfavo

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    December 15, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acacia Pharma Announces BYFAVO its Newly Approved Product for Procedural Sedation

    Details:

    US DEA has designated its procedural sedative BYFAVO™ (remimazolam injection) as a Schedule IV medicine. This designation is the schedule for drugs with a low potential for abuse and low risk of dependence and is consistent with that granted to many other benzodiazepine drugs.


    Lead Product(s): Remimazolam Besylate

    Therapeutic Area: Neurology Brand Name: Byfavo

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 06, 2020

    blank

    03

    Acacia Pharma

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Acacia Pharma

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Remimazolam Besylate

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Acacia Pharma Announces BYFAVO its Newly Approved Product for Procedural Sedation

    Details : US DEA has designated its procedural sedative BYFAVO™ (remimazolam injection) as a Schedule IV medicine. This designation is the schedule for drugs with a low potential for abuse and low risk of dependence and is consistent with that granted to many ot...

    Brand Name : Byfavo

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    October 06, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

    Details:

    Acacia Pharma has been assigned the US license to BYFAVO™ (remimazolam) for injection by Cosmo Pharmaceuticals NV. BYFAVO for injection is a very rapid onset/offset intravenous benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less.


    Lead Product(s): Remimazolam Besylate

    Therapeutic Area: Neurology Brand Name: Byfavo

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Acacia Pharma

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement July 15, 2020

    blank

    04

    Cosmo Pharmaceuticals

    Ireland
    arrow
    ASC 2024
    Not Confirmed

    Cosmo Pharmaceuticals

    Ireland
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Remimazolam Besylate

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Acacia Pharma

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Acacia Pharma Assigned US License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

    Details : Acacia Pharma has been assigned the US license to BYFAVO™ (remimazolam) for injection by Cosmo Pharmaceuticals NV. BYFAVO for injection is a very rapid onset/offset intravenous benzodiazepine sedative for use during invasive medical procedures lasting ...

    Brand Name : Byfavo

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    July 15, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cosmo Pharmaceuticals Announces US FDA Approval of BYFAVO™ (remimazolam injection)

    Details:

    The US Food and Drug Administration (FDA) has approved BYFAVO™ (remimazolam injection) for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.


    Lead Product(s): Remimazolam Besylate

    Therapeutic Area: Neurology Brand Name: Byfavo

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 02, 2020

    blank

    05

    Cosmo Pharmaceuticals

    Ireland
    arrow
    ASC 2024
    Not Confirmed

    Cosmo Pharmaceuticals

    Ireland
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Remimazolam Besylate

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Cosmo Pharmaceuticals Announces US FDA Approval of BYFAVO™ (remimazolam injection)

    Details : The US Food and Drug Administration (FDA) has approved BYFAVO™ (remimazolam injection) for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.

    Brand Name : Byfavo

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    July 02, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals

    Details:

    Acacia Pharma will be responsible for the marketing and distribution of ByFavo in the US in the context of its equity-for-product strategy.


    Lead Product(s): Remimazolam Besylate

    Therapeutic Area: Neurology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Small molecule

    Sponsor: Cosmo Pharmaceuticals

    Deal Size: $143.2 million Upfront Cash: $11.1 million

    Deal Type: Licensing Agreement January 09, 2020

    blank

    06

    Acacia Pharma

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Acacia Pharma

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Remimazolam Besylate

    Therapeutic Area : Neurology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Cosmo Pharmaceuticals

    Deal Size : $143.2 million

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals

    Details : Acacia Pharma will be responsible for the marketing and distribution of ByFavo in the US in the context of its equity-for-product strategy.

    Brand Name : Undisclosed

    Molecule Type : Small molecule

    Upfront Cash : $11.1 million

    January 09, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    INTERMEDIATES SUPPLIERS

    read-more
    read-more

    01

    Cohance Lifesciences

    India
    CPhI Worldwide, Milan
    Booth #4B1
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Methyl 3-((3S)-7-bromo-2-((2-hydroxypropyl)amino)-...

    CAS Number : 308243-54-1

    End Use API : Remimazolam Besylate

    About The Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commer...

    Cohance

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Shandong Boyuan Pharmaceutical

    China
    CPhI Worldwide, Milan
    Booth #3A142 & #3B136
    arrow
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShandong Boyuan is a Chinese manufacturer of GMP & CEP APIs & pharmaceutical intermediates.

    (3S)-(7-BroMo-2-oxo-5-pyridin-2-yl-2,3-dihydro-1H-...

    CAS Number : 308242-23-1

    End Use API : Remimazolam Besylate

    About The Company : We are one of the well-known manufacturers of key APIs & intermediates in China, with 20 years of experience & presence in 20+ countries. At Boyuan, we are comm...

    Shandong Boyuan Pharmaceutical

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDF Dossiers

    read-more
    read-more

    01

    Acacia Pharma

    United Kingdom
    ASC 2024
    Not Confirmed
    arrow

    Acacia Pharma

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info : RX

    Registration Country : USA

    REMIMAZOLAM BESYLATE

    Brand Name : BYFAVO

    Dosage Form : POWDER;INTRAVENOUS

    Dosage Strength : EQ 20MG BASE/VIAL

    Packaging :

    Approval Date : 2020-10-06

    Application Number : 212295

    Regulatory Info : RX

    Registration Country : USA

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    FDA Orange Book

    read-more
    read-more

    01

    ACACIA

    United Kingdom
    ASC 2024
    Not Confirmed
    arrow

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag United Kingdom
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    RLD : Yes

    TE Code :

    REMIMAZOLAM BESYLATE

    Brand Name : BYFAVO

    Dosage Form : POWDER;INTRAVENOUS

    Dosage Strength : EQ 20MG BASE/VIAL

    Approval Date : 2020-10-06

    Application Number : 212295

    RX/OTC/DISCN : RX

    RLD : Yes

    TE Code :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Patents

    read-more
    read-more

    01

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2031-11-07

    REMIMAZOLAM BESYLATE

    US Patent Number : 10052334

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 212295

    Patent Use Code : U-2968

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2031-11-07

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2027-07-10

    REMIMAZOLAM BESYLATE

    US Patent Number : 10961250

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 212295

    Patent Use Code : U-2968

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-07-10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2031-11-07

    REMIMAZOLAM BESYLATE

    US Patent Number : 9737547

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 212295

    Patent Use Code : U-2968

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2031-11-07

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2027-07-10

    REMIMAZOLAM BESYLATE

    US Patent Number : 9914738

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 212295

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-07-10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2034-01-13

    REMIMAZOLAM BESYLATE

    US Patent Number : 9827251

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 212295

    Patent Use Code : U-2968

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2034-01-13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2027-07-10

    REMIMAZOLAM BESYLATE

    US Patent Number : 9777007

    Drug Substance Claim :

    Drug Product Claim : Y

    Application Number : 212295

    Patent Use Code :

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-07-10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2027-07-10

    REMIMAZOLAM BESYLATE

    US Patent Number : 10472365

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 212295

    Patent Use Code : U-2968

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2027-07-10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2031-11-07

    REMIMAZOLAM BESYLATE

    US Patent Number : 10722522

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 212295

    Patent Use Code : U-2968

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2031-11-07

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2033-04-30

    REMIMAZOLAM BESYLATE

    US Patent Number : 9561236

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 212295

    Patent Use Code : U-2968

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2033-04-30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    ACACIA

    REMIMAZOLAM BESYLATE

    arrow
    ASC 2024
    Not Confirmed

    ACACIA

    United Kingdom
    arrow
    ASC 2024
    Not Confirmed

    Patent Expiration Date : 2031-11-07

    REMIMAZOLAM BESYLATE

    US Patent Number : 10342800

    Drug Substance Claim :

    Drug Product Claim :

    Application Number : 212295

    Patent Use Code : U-2968

    Delist Requested :

    Patent Use Description :

    Patent Expiration Date : 2031-11-07

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search